Expert Review of Vaccines

Papers
(The TQCC of Expert Review of Vaccines is 12. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)
ArticleCitations
Monkeypox pandemic containment: does the ACAM2000 vaccine play a role in the current outbreaks?90
Progress and challenges in Nipah vaccine development and licensure for epidemic preparedness and response77
Relationship between attitudes toward the effectiveness of vaccine, concerns about adverse reactions, and proactively taking SARS-Cov-2 vaccine for family among medical workers in Taizhou, China73
Effectiveness of an mRNA vaccine booster dose against SARS-CoV-2 infection and severe COVID-19 in persons aged ≥60 years and other high-risk groups during predominant circulation of the delta variant 69
Review of scientific evidence to support recommendations of the full-dose DTaP-IPV vaccination in pre-school age children in Italy63
Indirect protection from rotavirus vaccines: a systematic review63
Knowledge, attitudes, and perceptions towards pneumococcal vaccines among adults in the United States52
Expert review of global real-world data on COVID-19 vaccine booster effectiveness and safety during the omicron-dominant phase of the pandemic50
Parental category B vaccine hesitancy and associated factors in China: an online cross-sectional survey47
The protective effects of two varicella vaccination strategies: A Bayesian modeling study in two megacities in South China46
Comparative effectiveness of Omicron XBB 1.5-adapted COVID-19 vaccines: a systematic literature review and network meta-analysis45
Response to letter to the editor on a systematic review of invasive pneumococcal disease vaccine failures and breakthrough with higher-valency pneumococcal conjugate vaccines in children44
Response to Feemster KA et al. letter to the editor on Cost-effectiveness analysis for PCV13 in adults 60 years and over with underlying medical conditions which put them at an elevated risk of pneumo43
Post-marketing surveillance for the safety of the quadrivalent human papillomavirus vaccine: a retrospective real-world study in China41
Public health impact and cost-effectiveness of the adjuvanted RSVPreF3 vaccine for respiratory syncytial virus prevention among adults aged 50 years and older in Germany41
Addressing barriers to and strategies for herpes zoster vaccination in immunocompromised patients in Türkiye: an expert consensus41
Waning intra-season vaccine effectiveness against influenza A(H3N2) underlines the need for more durable protection41
Economic evaluations of 13-valent pneumococcal conjugate vaccine: a systematic review40
Clinical development of variant-adapted BNT162b2 COVID-19 vaccines: the early Omicron era39
Effectiveness of maternal vaccination with quadrivalent inactivated influenza vaccine in pregnant women and their infants in 2019-202037
Microarray patches: scratching the surface of vaccine delivery37
A review of evidence for pneumococcal vaccination in adults at increased risk of pneumococcal disease: risk group definitions and optimization of vaccination coverage in the United Kingdom37
Research progress on substitution of in vivo method(s) by in vitro method(s) for human vaccine potency assays36
The important lessons lurking in the history of meningococcal epidemiology36
Personal and contextual determinants of COVID-19 vaccination intention: a vignette study36
Batch-to-batch consistency trial of an adenovirus type-5 vector-based COVID-19 vaccine in adults aged 18 years and above35
Anti-COVID-19 vaccines and rare cases of cerebral venous sinus thrombosis with thrombocytopenia: what about the pragmatic benefit/risk evaluation for still unvaccinated young women35
Pre-erythrocytic malaria vaccines: RTS,S, R21, and beyond35
COVID-19 vaccination hesitancy in pregnant and breastfeeding women and strategies to increase vaccination compliance: a systematic review and meta-analysis35
Parental COVID-19 vaccine hesitancy: a cross-sectional survey in Italy33
Birth order and influenza vaccination: a comparative study of behaviors and intentions between first-time and second-time Chinese parents31
Comparing reactogenicity of COVID-19 vaccines: a systematic review and meta-analysis30
Who is more likely to hesitate to accept COVID-19 vaccine: a cross-sectional survey in China30
Montanide ISA-51: a promising adjuvant in cancer vaccine immunotherapy30
Immunization in pregnancy to protect pregnant people and their newborns against COVID-1929
Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT): A review of the evidence and expert opinion27
Impact of acellular immunization against pertussis; comparative experience of four countries in North, Central and South America26
Comparative assessment of myocarditis and pericarditis reporting rates related to mRNA COVID-19 vaccines in Europe and the United States26
Cost-effectiveness of cell-based influenza vaccine in France26
Cost-effectiveness analysis of adult pneumococcal conjugate vaccines for pneumococcal disease in Japan26
Looking to the future: is a universal coronavirus vaccine feasible?26
Adult risk groups for vaccine preventable respiratory infections: an overview of the UK environment26
Cost-effectiveness of bivalent respiratory syncytial virus prefusion F vaccine for prevention of respiratory syncytial virus among older adults in Germany25
Two decades of GSK rotavirus vaccine (RV1): a global analysis to estimate vaccination completion and deaths averted in children under 5 years25
The value of public-private collaborative real-world evidence platforms to monitor vaccine performance post authorization: DRIVE - a European initiative25
TAK-003: development of a tetravalent dengue vaccine24
Mechanisms of cellular and humoral immunity through the lens of VLP-based vaccines24
Comparing reactogenicity of COVID-19 vaccine boosters: a systematic review and meta-analysis24
COVID-19 vaccination and mask wearing behaviors in the United States, August 2020 - June 202124
Immunogenicity and safety of a live attenuated varicella vaccine in healthy subjects aged between 13 to 55 years: a double-blind, randomized, active-controlled phase III clinical trial in China23
Genetic predisposition to adverse events in Chinese children aged 3-24 months after diphtheria, tetanus, acellular pertussis and haemophilus influenzae type b combined vaccination23
Potential public health impact of the adjuvanted RSVPreF3 vaccine in adults aged 60 years and older: results from a modeling study in India and Southeast Asia23
Anti-neuraminidase immunity in the combat against influenza20
COVID-19 vaccine trials and sex-disaggregated data20
Regional molecular epidemiology of dengue and the potential optimization of its control through the use of vaccines. Report of the Arbovirus Committee of the Latin American Society of Pediatric Infect20
Duration of immunogenicity of high-dose and prolonged-schedule hepatitis B vaccine among patients with chronic kidney disease: A one year follow-up study in China20
Self-controlled case series design in vaccine safety: a systematic review20
Modeling the potential public health and economic impact of COVID-19 vaccination strategies using an adapted vaccine in Peru19
Travelers’ preferences for tick-borne encephalitis vaccination19
The burden of seasonal influenza: improving vaccination coverage to mitigate morbidity and its impact on healthcare systems19
Vaccines against mpox: MVA-BN and LC16m819
Adjuvant system AS01: from mode of action to effective vaccines19
Cost-effectiveness analysis of 20-valent pneumococcal conjugate vaccine (PCV20) to prevent pneumococcal disease in the Greek pediatric population19
An instrument to measure psychosocial determinants of health care professionals’ vaccination behavior: Validation of the Pro-VC-Be questionnaire19
In 30 years, gender-neutral vaccination eradicates oncogenic human papillomavirus (HPV) types while screening eliminates HPV-associated cancers19
Vaccination policies for dentists and other dental professionals in Europe: a systematic report18
Serotype-specific serum immunoglobulin G at 18 months of age following one or two doses of a primary series of 10-valent or 13-valent pneumococcal conjugate vaccine and a booster dose at nine months o18
Innovation and immunization program management: traceability and quality in Latin America and the Caribbean, laying the groundwork for a regional action plan18
Willingness to receive a booster dose of inactivated coronavirus disease 2019 vaccine in Taizhou, China18
Immunogenicity and safety of meningococcal vaccines, MenACWY-CRM and 4CMenB, in groups at increased risk for meningococcal disease18
A descriptive review on the real-world impact of Moderna, Inc. COVID-19 vaccines17
Preclinical advances and the immunophysiology of a new therapeutic Chagas disease vaccine17
Herpes zoster and simplex reactivation following COVID-19 vaccination: new insights from a vaccine adverse event reporting system (VAERS) database analysis17
Antibody persistence and revaccination recommendations of MenACWY-TT: a review of clinical studies assessing antibody persistence up to 10 years after vaccination17
Suspended cell lines for inactivated virus vaccine production17
The durability of vaccine-induced protection: an overview17
Predicting effectiveness of the V114 vaccine against invasive pneumococcal disease in children17
A benefit-cost analysis quantifying the broader socioeconomic value of adult respiratory vaccination programs in Japan17
Real-world impact of rotavirus vaccination in European healthcare settings: a systematic literature review16
Estimating the time required to reach HPV vaccination targets across Europe16
Major severe acute respiratory coronavirus-2 (SARS-CoV-2) vaccine-associated adverse effects; benefits outweigh the risks16
Safety of primary immunization with a DTwP-HBV/Hib vaccine in healthy infants: a prospective, open-label, interventional, phase IV clinical study16
Changes in serotype distribution and antimicrobial nonsusceptibility of Streptococcus pneumoniae among hospitalized children: Shenzhen, China, 2009–201916
Immunization in state of siege: the importance of thermostable vaccines for Ukraine and other war-torn countries and territories16
Synergistic activity of antibodies in the multicomponent 4CMenB vaccine16
Lessons from a decade of adult vaccine rollout in low- and middle-income countries: a scoping review15
Impact of rotavirus vaccination on diarrheal disease burden of children in South America15
A journey worth taking: global eradication of measles, rubella and congenital rubella syndrome15
Preferences and attitudes of healthcare providers towards pneumococcal vaccines for adults in the United States15
Toward an effective Staphylococcus vaccine: why have candidates failed and what is the next step?15
COVID-19 vaccines coverage and effectiveness against SARS-CoV-2 infection among residents in the largest Health Authority of Lazio region (Italy): a population-based cohort study15
Immunogenicity and reactogenicity of COVID-19 Pfizer-BioNTech (Bnt162b2) mRNA vaccination in immunocompromised adolescents and young adults: a systematic review and meta-analyses14
Public health impact and return on investment of the pediatric immunization program in Poland14
Making COVID-19 mRNA vaccines accessible: challenges resolved14
Resilience learning from the COVID-19 pandemic and its relevance for routine immunization programs14
Rebuilding vaccine confidence in Latin America and the Caribbean: strategies for the post-pandemic era14
Changes in vaccine administration trends across the life-course during the COVID-19 pandemic in the United States: a claims database study14
Screening of tumor antigens and immunogenic cell death landscapes of prostate adenocarcinoma for exploration of mRNA vaccine14
Have mRNA vaccines sentenced DNA vaccines to death?14
Will the mRNA vaccine platform be the panacea for the development of vaccines against antimicrobial resistant (AMR) pathogens?14
Next generation live-attenuated influenza vaccine platforms14
Mapping and ranking outcomes for the evaluation of seasonal influenza vaccine efficacy and effectiveness: a delphi study14
Effectiveness of the autumnal COVID-19 vaccine dose during the winter and summer waves of the 2023/24 season in Spain14
Expert review on global real-world vaccine effectiveness against SARS-CoV-213
Vaccination strategies for solid organ transplant candidates and recipients: insights and recommendations13
PPSV-23 recommendation and vaccination coverage in China: a cross-sectional survey among healthcare workers, older adults and chronic disease patients13
Options for the development of a bivalent vaccine against SARS-CoV-2 and influenza13
Safety, immunogenicity and immune-persistence of heterologous prime-boost immunization with BBIBP-CorV and ZF2001 against SARS-CoV-2 in healthy adults aged 18 years or older13
Cardiovascular safety of COVID-19 vaccines in real-world studies: a systematic review and meta-analysis13
Regulated microbe vaccines: from concept to (pre-clinical) reduction to practice13
Correspondence on ‘Herpes Zoster and Simplex reactivation following COVID-19 vaccination’13
Eyedrop vaccination: an immunization route with promises for effective responses to pandemics13
Health behaviors are largely not predictive of adverse events following influenza vaccination13
Emergence of mRNA vaccines in the management of cancer12
Correction12
Reverse engineering approach: a step towards a new era of vaccinology with special reference to Salmonella12
COVID-19 and vaccination: myths vs science12
Global pandemic preparedness: learning from the COVID-19 vaccine development and distribution12
Repeated vaccination and ‘vaccine exhaustion’: relevance to the COVID-19 crisis12
Time lapses between distribution of influenza vaccines to health authorities and their administration by General Practitioners (GPs) to older adults: a retrospective study over five influenza seasons 12
Subolesin: a 20-year path from discovery to an effective tick vaccine12
Correlates of protection for meningococcal surface protein vaccines: current approaches for the determination of breadth of coverage12
Vaccines against SARS-CoV-2 variants and future pandemics12
What are the challenges faced by COVID-19 vaccines?12
An overview: CRISPR/Cas-based gene editing for viral vaccine development12
Trends in adolescent and adult vaccination in pharmacy and medical settings in the United States, 2018–2024: a database study12
Acute otitis media pneumococcal disease burden and nasopharyngeal colonization in children due to serotypes included and not included in current and new pneumococcal conjugate vaccines12
Pneumococcal vaccination coverage among US adults enrolled in Medicaid and newly diagnosed with underlying medical conditions12
Vaccine clinical trials in low- and middle-income countries: a brief review of standard, newer and proposed approaches12
0.1396119594574